$CSTONE PHARMA-B (02616.HK)$ Clinical approvals continue to ...

Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.